C. Dubruc

846 total citations
38 papers, 670 citations indexed

About

C. Dubruc is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, C. Dubruc has authored 38 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pediatrics, Perinatology and Child Health, 8 papers in Pharmacology and 8 papers in Psychiatry and Mental health. Recurrent topics in C. Dubruc's work include Analytical Methods in Pharmaceuticals (5 papers), Pharmaceutical studies and practices (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). C. Dubruc is often cited by papers focused on Analytical Methods in Pharmaceuticals (5 papers), Pharmaceutical studies and practices (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). C. Dubruc collaborates with scholars based in France, United Kingdom and United States. C. Dubruc's co-authors include G. Bianchetti, P. Rosenzweig, Jean‐Paul Thénot, Alain Patat, P Vert, France Mentré, P. L. Morselli, Marie‐Jeanne Boutroy, J. P. Thenot and Philippe Monin and has published in prestigious journals such as Blood, Journal of Chromatography A and Journal of Affective Disorders.

In The Last Decade

C. Dubruc

37 papers receiving 614 citations

Peers

Countries citing papers authored by C. Dubruc

Since Specialization

Citations

This map shows the geographic impact of C. Dubruc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Dubruc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Dubruc more than expected).

Fields of papers citing papers by C. Dubruc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Dubruc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Dubruc. The network helps show where C. Dubruc may publish in the future.

Co-authorship network of co-authors of C. Dubruc

This figure shows the co-authorship network connecting the top 25 collaborators of C. Dubruc. A scholar is included among the top collaborators of C. Dubruc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Dubruc. C. Dubruc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A mechanism‐based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects 2011 ·British Journal of Clinical Pharmacology ·(unknown), Christine Veyrat‐Follet, Nicole Vivier, C. Dubruc, Gérard Sanderink, France Mentré, Emmanuelle Comets	16
2	The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials 2009 ·Journal of Thrombosis and Haemostasis ·Christine Veyrat‐Follet, Nicole Vivier, (unknown), C. Dubruc, Gérard Sanderink	30
3	Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance 2006 ·Fundamental and Clinical Pharmacology ·(unknown), (unknown), Frederic André, G. Bianchetti, C. Dubruc	36
4	New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans 2004 ·Fundamental and Clinical Pharmacology ·(unknown), (unknown), Daniel Francon, Rodney D. Adam, Philippe Lluel, C. Dubruc, Jean‐Paul Thénot	20
5	Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children 2001 ·Journal of Pharmacokinetics and Pharmacodynamics ·France Mentré, C. Dubruc, Jean‐Paul Thénot	37
6	Clinical pharmacology of befloxatone: a brief review 1998 ·Journal of Affective Disorders ·P. Rosenzweig, Alain Patat, O. Curet, Geneviève Durrieu, C. Dubruc, I. Zieleniuk, Eric Legangneux	17
7	Population Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients Using the Nonparametric Maximum Likelihood Method 1998 ·Journal of Pharmacokinetics and Biopharmaceutics ·(unknown), France Mentré, C. Dubruc, Jean‐Paul Thénot, Alain Mallet	22
8	Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling 1997 ·Journal of Pharmacokinetics and Biopharmaceutics ·(unknown), C. Dubruc, France Mentré, Sylvie Huet, Alain Mallet, Jean‐Paul Thénot	13
9	EEG, MAO-A inhibition, pharmacokinetics and safety of befloxatone in the elderly 1997 ·Human Psychopharmacology Clinical and Experimental ·Alain Patat, C. Dubruc, (unknown), Geneviève Durrieu, (unknown), (unknown), (unknown), P. Rosenzweig, (unknown)	3
10	Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine 1996 ·European Journal of Clinical Pharmacology ·O. Chosidow, C. Dubruc, Philippe Danjou, Eliane Fuseau, (unknown), G. Bianchetti, J. P. Thenot, S. Herson, P. Rosenzweig, J. Revuz	9
11	Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers 1996 ·The Journal of Clinical Pharmacology ·Alain Patat, F. Le Coz, C. Dubruc, (unknown), Geneviève Durrieu, (unknown), (unknown), O. Curet, I. Zieleniuk, H. Allain, P. Rosenzweig	16
12	Inhibition of Histamine‐Induced Skin Wheal and Flare after 5 days of Mizolastine 1996 ·The Journal of Clinical Pharmacology ·(unknown), Henri Caplain, (unknown), C. Dubruc, (unknown), P. Rosenzweig	13
13	Pharmacokinetic and bioavailability of diltiazem sustained‐release: influence of food and time of administration 1995 ·Fundamental and Clinical Pharmacology ·G. Bianchetti, Haleh Bagheri, Georges Houin, C. Dubruc, J. P. Thenot	3
14	Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 mg) after repeated administration in healthy volunteers 1995 ·European Journal of Clinical Pharmacology ·G. Bianchetti, C. Dubruc, P. Rosenzweig, Viqar Sultana, Georges Houin	5
15	EEG profile of litoxetine after single and repeated administration in healthy volunteers. 1994 ·British Journal of Clinical Pharmacology ·Alain Patat, (unknown), (unknown), P. Rosenzweig, C. Dubruc, G. Bianchetti, (unknown), L. Court	8
16	EEG profile of intravenous zolpidem in healthy volunteers 1994 ·Psychopharmacology ·Alain Patat, (unknown), (unknown), P. Rosenzweig, C. Dubruc, G. Bianchetti, L. Court, P.L. Morselli	49
17	Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects 1994 ·International Clinical Psychopharmacology ·Alain Patat, L. F. Gram, C. Dubruc, (unknown), (unknown), P. Rosenzweig	28
18	Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic 1994 ·Clinical Pharmacology & Therapeutics ·Alain Patat, (unknown), Élisabeth Van Gessel, Alain Forster, C. Dubruc, P. Rosenzweig	23
19	Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients 1993 ·Fundamental and Clinical Pharmacology ·(unknown), (unknown), Isabelle Étienne, (unknown), P. Rosenzweig, Philippe Danjou, C. Dubruc, G. Bianchetti	9
20	Pharmacokinetics of lndomethacin in the Premature Infant 1980 ·Developmental Pharmacology and Therapeutics ·G. Bianchetti, Philippe Monin, Francis Marchal, C. Dubruc, Marie‐Jeanne Boutroy, P. L. Morselli, P Vert	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact